Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma

BACKGROUND: Renal cell carcinoma of variant histology (vRCC) encompasses approximately 20% of RCC diagnoses. Due to a poor understanding of the different biologies of vRCCs, there is currently no standard of care for this type of tumor and guidelines are extrapolated from clear-cell RCC trials. A ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Saliby, Renee Maria, El Zarif, Talal, Bakouny, Ziad, Shah, Valisha, Xie, Wanling, Flippot, Ronan, Denize, Thomas, Harry Kane, M, Madsen, Katrine, Ficial, Miriam, Hirsch, Laure, Wei, Xiao, Steinharter, John, Harshman, Lauren, Vaishampayan, Ulka, Severgnini, Mariano, McDermott, David, Mary Lee, Gwo-Shu, Xu, Wenxin, Van Allen, Eliezer, McGregor, Bradley, Signoretti, Sabina, Choueiri, Toni, McKay, Rana, Braun, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Biomarkers in Kidney Cancer Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445571/
http://dx.doi.org/10.1093/oncolo/oyad216.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445571/
http://dx.doi.org/10.1093/oncolo/oyad216.026

Ejemplares similares